KOD Stock Chart & Stats
$749.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$51.00 - $749.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$45.93B
Enterprise Value$2.34K
Total Cash (Recent Filing)$169.53M
Total Debt (Recent Filing)$155.99M
Price to Earnings (P/E)―
Beta4.50
Next Earnings
Aug 19, 2026EPS Estimate
-16.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.17
Shares Outstanding62,578,440
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)9.45
Price to Sales (P/S)0.00
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,050.53Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
KOD FAQ
What was Kodiak Sciences’s price range in the past 12 months?
Kodiak Sciences lowest stock price was $51.00 and its highest was $749.00 in the past 12 months.
What is Kodiak Sciences’s market cap?
Kodiak Sciences’s market cap is $45.93B.
When is Kodiak Sciences’s upcoming earnings report date?
Kodiak Sciences’s upcoming earnings report date is Aug 19, 2026 which is in 25 days.
How were Kodiak Sciences’s earnings last quarter?
Currently, no data Available
Is Kodiak Sciences overvalued?
According to Wall Street analysts Kodiak Sciences’s price is currently Undervalued.
Does Kodiak Sciences pay dividends?
Kodiak Sciences does not currently pay dividends.
What is Kodiak Sciences’s EPS estimate?
Kodiak Sciences’s EPS estimate is -16.77.
How many shares outstanding does Kodiak Sciences have?
Kodiak Sciences has 62,578,440 shares outstanding.
What happened to Kodiak Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kodiak Sciences?
Currently, no hedge funds are holding shares in MX:KOD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kodiak Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,050.53 (― Downside)
$1,050.53 (― Downside)
Blogger Sentiment
Bullish
MX:KOD Sentiment 70%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
494.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.72%
Trailing 12-Months
Company Description
Kodiak Sciences
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
KOD Stock 12 Month Forecast
Average Price Target
$1,050.53